echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA approves AbbVie's JAK inhibitor Rinvoq for atopic dermatitis

    FDA approves AbbVie's JAK inhibitor Rinvoq for atopic dermatitis

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The U.
    S.
    Food and Drug Administration announced today that it has approved an expanded indication for AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in adults or children 12 years and older who have not responded to prior therapy and are The condition cannot be controlled by other treatments, or other treatments should not be used

    .
    This is another JAK inhibitor approved by the FDA today for the treatment of atopic dermatitis

    .

    Upadacitinib is a selective and reversible JAK inhibitor
    .
    In August 2019, it received U.
    S.
    FDA approval for the treatment of adults with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to methotrexate

    .

    The FDA approval was based on a large Phase 3 development program that evaluated 2,500 patients across 3 studies, approximately 52% of whom had previously received systemic atopic dermatitis therapy
    .

    The study showed that upadacitinib (15 mg and 30 mg orally daily) as monotherapy, and in combination with topical corticosteroids, met all primary and secondary clinical endpoints and achieved EASI 90 and EASI after 16 weeks of treatment The proportion of patients with 100 was also significantly higher
    .
    In all three studies, the researchers observed significant improvements in the degree of pruritus in patients with the drug, with effects seen as early as one week after administration

    .

    ▲The specific results of 3 clinical trials (picture source: Reference [1])

    In terms of safety, the data observed in the treatment groups were similar to the safety profile previously observed in patients with rheumatoid arthritis
    .
    Other specific adverse reactions associated with atopic dermatitis include eczema herpeticum/Kaposi's varicelliform eruption

    .
    The therapy may also carry potentially serious adverse effects associated with JAK inhibitors, including serious infections, increased risk of death in patients 50 and older with at least one cardiovascular risk factor, cancer and immune system problems, and cardiovascular disease risk and thrombosis

    .

    "Despite available treatments, many patients with moderate-to-severe atopic dermatitis suffer from endless itching that requires scratching," said Emma Guttman-Yassky, professor of dermatology at Mount Sinai School of Medicine.
    "In clinical trials, upadacitinib was Demonstrated robust relief in skin and pruritus symptoms, may help patients whose diseases are not adequately controlled, changing their treatment goals

    .
    As an oral tablet with two doses, upadacitinib could also be a tool in a physician's toolbox supplementation, helping them make a significant difference in the lives of patients with moderate-to-severe atopic dermatitis

    .
    "

    References:

    [1] US FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis, Retrieved January 14, 2022, from https:// us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis-301461377.
    html

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.